GURUFOCUS.COM » STOCK LIST » USA » NAS » Neuronetics Inc (NAS:STIM) » Definitions » Cash Ratio
Switch to:

Neuronetics Cash Ratio

: 3.86 (As of Jun. 2022)
View and export this data going back to 2018. Start your Free Trial

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Neuronetics's Cash Ratio for the quarter that ended in Jun. 2022 was 3.86.

Neuronetics has a Cash Ratio of 3.86. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Neuronetics's Cash Ratio or its related term are showing as below:

STIM' s Cash Ratio Range Over the Past 10 Years
Min: 0.98   Med: 3.82   Max: 11.3
Current: 3.86

During the past 6 years, Neuronetics's highest Cash Ratio was 11.30. The lowest was 0.98. And the median was 3.82.

STIM's Cash Ratio is ranked better than
75.21% of 242 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.31 vs STIM: 3.86

Neuronetics Cash Ratio Historical Data

The historical data trend for Neuronetics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuronetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash Ratio
Premium Member Only 2.43 7.71 2.77 3.72 6.14

Neuronetics Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Cash Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.18 2.12 6.14 6.29 3.86

Competitive Comparison

For the Diagnostics & Research subindustry, Neuronetics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Neuronetics Cash Ratio Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Neuronetics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Neuronetics's Cash Ratio falls into.



Neuronetics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Neuronetics's Cash Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Cash Ratio (A: Dec. 2021 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=96.339/15.703
=6.14

Neuronetics's Cash Ratio for the quarter that ended in Jun. 2022 is calculated as:

Cash Ratio (Q: Jun. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=73.027/18.937
=3.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuronetics  (NAS:STIM) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Neuronetics Cash Ratio Related Terms

Thank you for viewing the detailed overview of Neuronetics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuronetics Business Description

Neuronetics logo
Traded in Other Exchanges
Address
3222 Phoenixville Pike, Malvern, PA, USA, 19355
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Executives
Cannell Capital Llc 10 percent owner 245 MERIWETHER CIRCLE ALTA WY 83414
Rosengarten Megan director C/O NEURONETICS, INC. 3222 PHOENIXVILLE PIKE MALVERN PA 19355
Cascella Robert director C/O HOLOGIC, INC. BEDFORD MA 01730
Shook Bruce Joseph director 162 CRICKET AVE ARDMORE PA 19003
Jaeger Wilfred E director C/O THREE ARCH PARTNERS 3200 ALPINE RD PORTOLA VALLEY CA 94028
Bakewell John K director C/O LANTHEUS MEDICAL IMAGING, INC. 331 TREBLE COVE ROAD NO. BILLERICA MA 01862
Conley Sheryl L director C/O NEURONETICS, INC. 3222 PHOENIXVILLE PIKE MALVERN PA 19355
Muir Glenn P director C/O HOLOGIC, INC. BEDFORD MA 01730
Sullivan Keith J director, officer: President and CEO C/O RELIANT TECHNOLOGIES, INC. 464 ELLIS STREET MOUNTAIN VIEW CA 94043
Macan William Andrew officer: Sr. VP, GC, CCO and Secretary 24275 KATY FREEWAY, SUITE 600 KATY TX 77494
Harper Gregory officer: VP of Prod. Dev. & Operations C/O NEURONETICS, INC 3222 PHOENIXVILLE PIKE MALVERN PA 19355
Furlong Stephen officer: CFO C/O NEURONETICS, INC. 3222 PHOENIXVILLE PIKE MALVERN PA 19355
Tropsha Yelena officer: VP of Commercial Access C/O NEURONETICS, INC 3222 PHOENIXVILLE PIKE MALVERN PA 19355
Farley Brian E director 2200 ZANKER ROAD SUITE F SAN JOSE CA 95131
Guthrie Daniel officer: Chief Commercial Officer C/O NEURONETICS, INC 322 PHOENIXVILLE PIKE MALVERN PA 19355

Neuronetics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)